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Malaria is one of the leading causes of death worldwide and has been suggested as the most potent type of
selection in humans in recent millennia. As a result, genes involved in malaria resistance are excellent examples of
recent, strong selection. In 1949, Haldane initially suggested that infectious disease could be a strong selective force
in human populations. Evidence for the strong selective effect of malaria resistance includes the high frequency of
a number of detrimental genetic diseases caused by the pleiotropic effects of these malaria resistance variants,
many of which are “loss of function” mutants. Evidence that this selection is recent comes from the genetic dating
of the age of a number of these malaria resistant alleles to less than 5,000 years before the present, generally much
more recent than other human genetic variants. An approach to estimate selection coefficients from contemporary
case–control data is presented. In the situations described here, selection is much greater than 1%, significantly
higher than generally observed for other human genetic variation. With these selection coefficients, predictions are
generated about the joint change of alleles S and C at the β-globin locus, and for α-thalassaemia haplotypes and S,
variants that are unlinked but exhibit epistasis. Population genetics can be used to determine the amount and
pattern of selection in the past and predict selection in the future for other malaria resistance variants as they are
discovered.
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Malaria is one of the leading causes of death worldwide
and has been suggested as the most potent type of selec-
tion in humans in recent millennia [1]. As a result, genes
involved in malaria resistance are excellent examples of
recent, strong selection. Perhaps best known is the sickle
cell haemoglobin variant, which is often used as an ex-
ample of heterozygote advantage. In addition, G6PD de-
ficiency illustrates strong selection at an X-linked locus,
β-globin variants S, C, and E and G6PD deficiency var-
iants A-, Med, and Mahidol show how selective differ-
ences can be the result of a single-nucleotide change.
Further, HLA-B53 illustrates how gene conversion can
result in an adaptive allele, and α-thalassaemia shows
how selection can operate on loci that have different
copy numbers.
Haldane, known as one of the three founders of popu-
lation genetics, is often recognized with first suggesting
that disease could be an important evolutionary force inCorrespondence: philip.hedrick@asu.edu
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reproduction in any medium, provided the orhumans. Although his general review [2] is often cited
for this concept, this hypothesis was presented in more
detail in 1948 [3] where he suggested that β-thalassaemia
heterozygotes had an increased fitness in the presence of
malaria. Therefore, citation of [3] seems more correct for
the hypothesis that malaria resistance in humans might
be genetically determined and evolutionarily significant
[4-6].
The first generally recognized evidence for genetic re-
sistance to malaria in humans was in 1954 [7] for sickle-
cell haemoglobin heterozygotes AS. Overall, the “malaria
hypothesis” of Haldane that some human diseases such
as thalassaemia are polymorphisms and provide hetero-
zygote advantage because of the trade-offs between the
advantages of resistance to malaria and negative effects
due to the disease, is now widely accepted but the exact
means of disease resistance have often been difficult to
elucidate.
As documentation for the contemporary influence of
malaria, in 2010 there were 216 million clinical cases
and an estimated 863,000 deaths from malaria [8],This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Although these levels have declined globally 25% since
2000, another analysis estimated that the annual mortal-
ity may be much higher than this level at 1.24 million
[9].
The impact of malaria is thought to have increased
between 10,000 and 5,000 years ago when there were
the beginnings of agriculture and consequently more
human settlements. During this period, the numbers of
both the human population and the mosquito vector
increased, resulting in higher spread of malaria [10].
Recent molecular studies suggest that malaria in
humans from Plasmodium falciparum may have origi-
nated from gorillas [11,12]. Using these data, an initial
timeline for the origin of P. falciparum as a human
pathogen suggests that it may be more recent than pre-
viously thought [13].
The past geographic extent of malaria and the distri-
bution of malaria resistance variants broadly correspond
[14-16]. For example, P. falciparum is found across Af-
rica and Asia, as are the variants of haemoglobin and
G6PD that provide malaria resistance. In regions of high
endemic malaria, such as sub-Saharan tropical Africa
and lowland Melanesia, there are often several variants.
In contrast, variants do not exist in areas without past
malaria, with the exception of ancestry from new immi-
grants [17]. To illustrate, the common malaria resistant
alleles are not present in New World natives [18], pre-
sumably because their ancestors were unexposed to
malaria and malaria only came to the Americas during
the transatlantic slave trade between the 16th and 19th
centuries [19]. Further, microgeographic variation of
β-thalassaemia in Sardinia and the past presence of
malaria are concordant [20] and α-thalassaemia and
β-thalassaemia variation in Melanesia is associated with
malaria presence [21,22].
Some resistance alleles for malaria are distinctive and
others are very general. To illustrate, geographically
separated Duffy alleles in Papua New Guinea and Africa
result from changes at the same exact genomic location,
33 nucleotides upstream from the start codon. Similarly,
the β-globin malaria resistance alleles S and C occur
from different changes at the same codon. In contrast,
there are many changes that modify levels of expression
and provide malaria resistance for G6PD deficiency,
α-thalassaemia, and β-thalassaemia.
It is significant that malaria resistance genes are often
extremely variable, for example, the malaria resistance
genes ABO, G6PD, HLA, α-globin, and β-globin, are
some of the most variable human genes. Such variation
might be because disease resistance genes have high
amounts of standing variation or because these genes
have high mutation rates and produce new adaptive
alleles very quickly.There are several current first-rate reviews of the
mechanisms of malaria resistance and evaluations of the
malaria resistance genes [1,23-26] and in an extensive
recent review, many aspects of the population genetics
of malaria resistance were examined [6]. Therefore, the
focus here will be on the data indicating the very strong
and recent selection for malaria resistance in humans. In
addition, it will be shown how the expected change
when there is strong selection for malaria resistance var-
iants can be predicted with population genetics models.
Strength of selection
Pleiotropic disease effects
Strong selection for malaria resistance has increased,
due to pleiotropic effects, the frequency of genetic dis-
eases, such as G6PD deficiency, the thalassaemias, and
ovalocytosis. For example, it has been suggested that this
has caused a worldwide problem and has resulted in
300,000 newborns each year with haemoglobin maladies
[27]. These pleiotropic effects explain why such disor-
ders are the most common genetic diseases [28]. It is
also possible that some other diseases may be in high
frequency because of the pleiotropic effects of malaria
resistance variants [1].
Around 400 million people (worldwide prevalence of
4.9%) are affected with G6PD deficiency, the most com-
mon enzymopathy in humans [29]. Even though people
with G6PD deficiency are often asymptomatic, various
factors that result in oxidative stress can cause disease
episodes. To illustrate, fava beans can cause severe
haemolytic anaemia (favism) for individuals with the
Med G6PD deficiency.
Perhaps related to the high frequency of diseases
related to genes conferring resistance to malaria is that
many of resistance variants, such as G6PD deficiency,
the thalassaemias, sickle-cell anaemia, and ovalocytosis,
are “loss of function” mutants and lead to reduced ex-
pression or altered gene product. Sometimes these var-
iants result in disease because of their pleiotropic effects.
Or, in other situations, there is no cost to the change in
expression or gene product, as appears to be the case for
the Duffy “null” variants and for β-globin gene allele C.
Age of selective variants
Many malaria resistance genetic variants appear to be
recent polymorphisms and have been generated in the
last 5,000 to 10,000 years or less (see Table 1 and below).
These variants appear to date to the time when severe
malaria first became an important human evolutionary
factor. From this, one can surmise that they were not
malaria resistance alleles in ancestral species, i.e., they
are not trans-specific polymorphisms, and that they
most likely were the result of standing variation or gen-
erated by new mutations. Homologous resistance alleles
Table 1 Estimated age of malaria resistance variants in
years (assuming a 25-year generation length) and the
selection coefficient (estimated or assumed), — indicates
no selection (neutrality) is assumed
Gene
allele Age Selection coefficient Reference
β -globin
S 1,440 0.152 [34]
C 2,810 0.06 [36]
E 2,510 0.079 [39]
G6PD
A- 6,360 0.044 [40]
A- 1,000 0.25 [41]
Med 3,330 0.034 [40]
Mahidol 1,580 0.23 [42]
HLA-B
B53 2,150 0.041 [6]
Duffy
ES (null) 33,000 — [49]
ES (null) 10,000 — [50]
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they are, the variants are different from human variants
[33].
The age of S alleles has been estimated from the
amount of association (linkage disequilibrium) in se-
quence near the HBB locus. To illustrate, all samples of
S from eastern Senegal had the same haplotype [34]. As-
suming that selection for AS was 0.152 higher than for
AA, the estimated age of this S allele was 1,440 years
(see Table 1) [34]. Assuming that this allele was in low
frequency (standing variation), it is likely that this age
indicates the number of years since selection started to
increase this allele.
Overall, there might have been five different mutations
originating the S allele from the A allele. This conclusion
is based on the presence of these variants in almost non-
overlapping geographic regions, one found in both India
and Saudi Arabia and four others in different parts of
Africa, and the large differences in DNA sequence for
genetic regions linked to S, resulting in different haplo-
types in different geographic regions. The Mediterranean
S alleles appear related to the African S haplotypes, par-
ticularly the Benin haplotype [14]. Recent parallel adap-
tation of different S alleles is consistent with an
encompassing population genetics model [35].
In addition, Table 1 gives the estimated or assumed se-
lection coefficient for different variants. For example, a
selection coefficient of 0.152 for S indicates that the
sickle-cell heterozygote AS has a 15.2% advantage over
the normal homozygote AA. As a comparison, aselective advantage of more than a few per cent is un-
usual for other human genes.
A joint estimate of the age of the C allele and the se-
lection coefficient was approximated with a coalescent
approach [36]. The allele age was estimated to be 2,810
years and a selection coefficient of 0.06. More than one
mutational origin for the E allele in Thailand is indicated
[37]. On the other hand, the Chinese E allele has the
same haplotype as in Thailand [38], implying the same
origin. The age of the E allele was estimated to be about
2,510 years [39] and selection of 0.079.
Different ways have been used to estimate the age of
G6PD mutants (Table 1). Using simulations, estimation
of the age and selection for the A- allele was 6,360 years
with selection of 0.044 and for the Med allele was 3,330
years and selection of 0.034 [40]. Using Bayesian meth-
ods, the estimated age of A- was only 1,000 years and se-
lection was 0.25 [41] and the age of the Mahidol allele
was 1,580 years with selection of 0.23 [42]. These esti-
mates may differ because those in [40] used microsatel-
lite loci and those in [41] used sequence data.
The age of the HLA-Bw53 variant can be estimated
using the approach below to estimate s (with OR = 0.59,
m = 0.1, so that s = 0.041) and iteration of population
genetic equations. Therefore, it would take approxi-
mately 2,150 years for Bw53 to reach 0.25 [6]. This time
is substantially less than the time that strong selection in
Africa for malaria resistance is thought to have occurred.
There are several other malaria resistant variants that
appear to be recent but for which there has been no for-
mal estimation of their age. For example, out of about
80 deletions that result in α+ thalassaemia, four common
ones have different geographic distributions; for ex-
ample, deletion –α3.7 is found nearly worldwide but is
most common in Africa, deletion –α 4.2 has a high fre-
quency in southeast Asia, and – α 3.7I is found most
commonly in African, Indian and Mediterranean popula-
tions [14]. In addition, there are a number of mutants
that have very limited geographic distributions. The age
of these mutants has not been estimated, but their nar-
row distributions indicate recent generation.
Most of the β-thalassaemias are the result of single nu-
cleotide substitutions or small insertions or deletions.
Around 200 β-thalassaemias variants are known and
they also have narrow geographic distributions suggest-
ing that these changes indicate independent mutations
and have been recently generated. β-thalassaemia var-
iants in carriers are in frequencies from 5 to 20%, some-
what lower in frequency than α- thalassaemia variants
[43].
A mutation in gene SLC4A1 (erythrocyte Band 3 pro-
tein gene) found in Papua New Guinea and Malaysia
results from a 27-nucleotide (9-amino acid) deletion.
This genetic region is conserved throughout species [44]
Table 2 Frequency of different genotypes in healthy
(control) subjects (fc) and in malaria (diseased) patients
(fd) [56]
Genotype
AA AC AS CC SC SS
fc 0.664 0.217 0.095 0.016 — –
fd 0.804 0.164 0.028 0.001
OR 2.070 0.708 0.268 0.072 — —
Relative fitness 0.95 1.03 1.08 1.10 — —
0.86 0.94 0.98 1 0.50 0.11
The OR values for the genotypes and the estimated relative fitnesses are given
(m = 0.1). In the bottom row, these values are standardized by the fitness of
genotype CC, the genotype with the highest fitness [53].
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ical red blood cell shape, and anaemia in heterozygotes.
Even in progeny from matings between heterozygotes,
homozygotes have not observed, indicating they are le-
thal [45]. The lethality of homozygotes and the high re-
sistance of heterozygotes to malaria suggest that this
variant has properties not very different from the S allele
because the advantage to heterozygotes in resistance off-
sets the cost in fitness in homozygotes. Because of its
limited distribution, it is thought to be a recent
mutation.
There are several variants that provide resistance to
malaria that appear to be older. For example, there are
two antigens A and B produced by alleles FY*A and
FY*B at the Duffy blood group locus [46,47]. Many
African-Americans and Africans do not have either allele
and have another allele, known generally as a Duffy null
allele. This allele, FY*BES, is in very high frequency in
most of Africa and provides resistance to malaria species
Plasmodium vivax, but not to P. falciparum [48].
The estimated age of the FY*BES allele, based on se-
quence analysis, is around 33,000 years [49], while the
estimated age of this allele using microsatellite data is
around 10,000 years ago [50]. The earlier estimated ori-
gin may be more consistent with the early impact of
P. vivax on human mortality. Surprisingly, a Duffy allele
in low frequency (0.022) in Papua New Guinea, also dif-
fers from FY*A in the same exact sequence as does the
FY*BES allele found in Africa [51]. The low frequency of
this allele is probably because of its recent origin, a situ-
ation seen in the pattern of alleles at closely linked loci
[51].
Examples of strong selection and change in allele
frequency
As illustration, here two examples are given of fast
expected genetic changes over time due to strong selec-
tion at genes conferring resistance to malaria. Both
examples are ones in which there are two resistant var-
iants in one population, one in which the genetic var-
iants are different alleles at the same gene (S and C) and
the other where the genetic variants are different alleles
at different genes but there is epistasis between these
variants (S and α-thalassaemia). Before these examples
are described, an approach will be briefly introduced to
estimate the extent of selection at these variants using
contemporary case–control data (see [6] for details).
Estimation of selection
A general approach to determine the risk of individuals
with a given genotype getting a disease, relative to that
in the rest of the population, is to calculate the odds
ratio (OR) as OR = [fd(1 – fc)]/[fc(1 - fd)] where the fre-
quencies of the genotype in control and diseased groupsare fc and fd, respectively. For example, the selection co-
efficient for the AS heterozygote can be estimated as s =
m(1 – OR) where m is the rate of non-genotype specific
mortality from malaria (generally the mortality given
that an individual has severe malaria) [52,53].
To illustrate how OR and s can be calculated, data
from a large study of malaria in The Gambia can be used
to determine the effect of sickle-cell variation on the
presence of severe malaria [54]. In 619 children with se-
vere malaria, only seven (0.012) were heterozygous AS.
On the other hand, in 510 other children, who were out-
patients and termed “mild controls”, many more 66
(0.129) were AS. Therefore, OR = 0.082, indicating very
great protection from severe malaria for AS genotypes.
A value of 0.07 for m was suggested [52] while, a value
of at least m = 0.1 may be appropriate [10,55]. For the
AS genotype, if OR = 0.082 and m = 0.1, then s = 0.092.
Increase of allele C in the presence of allele S
The polymorphic structural variants at the β-globin
locus, S and C, both are malaria resistance alleles. Vari-
ant S is more widespread than C, which is in sub-
Saharan Africa, but they both occur in a number of
populations. Although some early studies suggested a
stable polymorphism of these variants, a Burkina Faso
sample [56] indicated the C allele would become fixed
over time [53,57].
In the Burkina Faso sample, the genotypes AC, AS,
and CC showed relative resistance to malaria and AA
showed relative susceptibility [56]. The frequencies of
these genotypes are given in Table 2 in both control and
disease groups along with OR values. Fitnesses for geno-
types SC and SS were based on deviations from Hardy-
Weinberg proportions [53]. If m = 0.1, the relative
fitness are given at the bottom in Table 2.
With these fitnesses, when S is introduced to a popula-
tion with only the A allele, it will go to a stable equilib-
rium with the frequency of S = 0.12. When C is
introduced to a population with only the A allele, it will
increase in frequency to fixation in a little more than
Table 3 Estimated relative survival (fitness) values for the
two-locus genotypes based on the data from [59] (see [6]
for details)
α-globin genotype
β- globin genotype αα/αα −a/αα −α/−α
AA 0.55 0.68 0.70
AS 1 0.91 0.55
SS 0 0 0
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their stable equilibrium, then C can enter the population
and eventually increase to fixation after about 5,000
years (Figure 1).
These results occur because genotype CC has the
highest relative fitness of the genotypes. In addition, it
might clarify situations, such as in the Dogon people of
Mali who have a high frequency of C and a low S fre-
quency [58]. In addition, and of public health conse-
quence, the mean fitness of the population is about 11%
higher when fixed for C than when it is polymorphic for
A and S because of the absence of sickle-cell anaemia
and higher resistance to malaria.
Effect of epistasis between alleles S and α+-thalassaemia
Sickle cell anaemia and α+-thalassaemia both occur in
some sub-Saharan African populations. The adult
haemoglobin molecule is composed for two subunits of
each of the α-globin and β-globin molecules. As a result,
it is not unexpected that there could be gene-gene inter-
action, or epistasis, at these loci for fitness. In a Kenyan
population, these disorders were both present [59] and
when the two disorders were inherited together in the
same individual, the protection from malaria given indi-
vidually by each allele was lost (see also [60]). This inter-
action, or negative epistasis, could be part of the
explanation why α+-thalassaemia does not appear fixed
in sub-Saharan populations. A traditional population
genetics approach is used here to examine this situation,
for an epidemiological approach, see [59,61,62]
The relative viabilities (fitnesses) of the different two-
locus genotypes (Table 3) were based on genotype-

















C(S initially at 0.12)
Figure 1 The increase in frequency of allele C when it begins at
a frequency of 0.01 (solid lines) both when S is absent and
when S begins at its equilibrium frequency of 0.12 [53]. The
change in frequency of S is also given for the last situation (broken
line).With a wild-type genotype at both genes, the estimated
relative fitness is only 0.55. The presence of S in AS and
the presence of −α in both genotypes −α/αα and −α/−α
increases the estimated relative fitness, given normal
genotypes at the other locus. However, the relative sur-
vival is reduced to only 0.55 when there is an AS geno-
type and homozygosity for −α, the same as the relative
fitness for the wild-type genotype.
This array of relative fitness values illustrates several
things. First, there is a stable polymorphism with S equal
to 0.309 when only the normal αα haplotype at the
a-globin gene is present (first column). Second, variant
–α haplotype would be fixed when only the normal A
allele is present at the β-globin locus (first row) because
the –α/−α genotype has the highest fitness. In addition,
some two-locus behaviour can be intuited by looking at
these viability values further. For example, if the popula-
tion is fixed for –α/–α it does not appear that S can
enter the population because AA –α/−α > AS −α/−α
(Table 3).
Using iterations of two-locus gamete frequency equa-
tions with selection [63], more details of the genetic be-
haviour of gametes with this two-locus fitness array are
observed. For example, if –α is polymorphic, there is an
unstable equilibrium so that –α will either increase or
go to a two-locus equilibrium, depending upon its initial
frequency, if S is introduced into the population. Figure 2
presents this situation where the initial frequency of S is
0.01 and the initial frequency of –α is either 0.55 or
0.65. The frequency of –α initially increases for 0.55 and
then approaches the two-locus equilibrium at 0.272. On
the other hand, when the initial frequency is 0.65, it
increases to unity while S initially increases but then
decreases to 0 (for further discussion see [6]). Notice
that although the amount of epistasis between the genes
is high, the time for these changes to occur is quite long.
Conclusions
Obviously, Haldane [3] was correct to point out that
malaria resistance in humans was a significant evolution-
ary factor. Malaria resistance genes comprise some of
the most widely accepted examples of strong positive se-
lection in humans. Overall, the original “malaria hypoth-















- (initially at 0.55)
- (initially at 0.65)
Figure 2 The change in the frequency of –a where the initial
frequency is either 0.55 or 0.65 using the relative fitnesses in
Table 3 and the initial frequency of S is 0.01.
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been proven correct. However, much is still to be
learned about actual mechanisms of protection, other
genes that confer resistance, and the population genetics
of this variation.
Malaria resistance offers cases of a number of aspects
of population genetics, particularly situations of recent,
strong selection. Overall, many of these resistance var-
iants appear less than 5,000 years old, much more recent
than for most human variants. They also have selection
coefficients significantly larger than 1%, much stronger
than for most human variants. Population genetics will
probably be even more important in understanding the
joint impact of multiple malaria resistance variants in
the future. Two situations are examined here, and it is
shown that in populations segregating for S and C, selec-
tion is expected to eliminate S and fix C. Also, depending
upon the starting frequencies, in populations segregating
for α-thalassaemia and S, either the α -thalassaemia
haplotype will become fixed and the S allele eliminated
or a stable equilibrium of both variants will occur be-
cause of negative epistasis.
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